Cyclin-dependent kinase inhibitor AT7519 as a potential drug for MYCN-dependent neuroblastoma

PURPOSE: MYCN-dependent neuroblastomas have low cure rates with current multimodal treatment regimens and novel therapeutic drugs are therefore urgently needed. In previous pre-clinical studies we have shown that targeted inhibition of cyclin-dependent kinase 2 (CDK2) resulted in specific killing of...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Cancer Res
Päätekijät: Dolman, M. Emmy M., Poon, Evon, Ebus, Marli E., den Hartog, Ilona J.M., van Noesel, Carel J.M., Jamin, Yann, Hallsworth, Albert, Robinson, Simon P., Petrie, Kevin, Sparidans, Rolf W., Kok, Robbert J., Versteeg, Rogier, Caron, Huib N., Chesler, Louis, Molenaar, Jan J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2015
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4645454/
https://ncbi.nlm.nih.gov/pubmed/26202950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-0313
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia